Not sure why there is a debate here over the results … strong growth recorded, material improvement in sales in July 2024 compared to last July with solid growth forecasted for rest of the FY. Changes to reimbursement to significantly benefit Eye by year’s end. A lot of positives in the result.
Patient holders should hopefully be rewarded in due time.
Ann: Full Year Financial Results, page-123
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.010(5.26%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.0¢ | $17.13K | 91.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 80630 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 37705 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |